With more than 35 years of experience, Midas Pharma brings proven expertise to every stage of the biopharmaceutical product life cycle. As a fully-fledged pharmaceutical company with EU GMP/GDP/WDA and MIA licenses, we offer a complete and reliable infrastructure tailored to your needs, whether you are an innovative start-up or an established biopharmaceutical company. 

Combining scientific expertise with a robust global network, Midas Pharma delivers integrated end-to-end solutions that accelerate your path from early-stage R&D to market. We provide the insight, infrastructure, and commitment needed to achieve your goals with confidence and to succeed in the competitive biopharmaceutical landscape. 

Your key benefits:  

• Process development: Expertise in biotechnological and chemical processes, covering preclinical development to commercial manufacturing.  

• Analytical services: Comprehensive structural and functional analysis that delivers precise insights into your molecule; tailored solutions, aligning technical accuracy with strategic goals through a holistic approach. 

• Starting materials, intermediates, drug substance, drug product, fill and finish (non GMP and GMP quality): Robust supply chain, including documentation in compliance with the authority requirements worldwide.  

• Novel autoinjector platform: Innovative solutions that overcome key challenges in subcutaneous delivery – enabling the injection of small and large volumes, especially but not only for high concentrated biologics.  

• GMP services: From EU QP release to global import/export: guaranteeing your products meet all regulatory standards.

• Market entry strategy: Guidance through the process of entering target markets, including due diligence and clinical trials. 

• Licensing: Structured licensing process, including partner identification, due diligence, contract negotiation, and ongoing support to ensure successful partnerships. 

• Commercial operations: Comprehensive wholesale solutions along with marketing authorization holder (MAH) and pharmacovigilance (PV) services.